SUPER: Product Description
Voiceover: All known insulins are composed of two polypeptide chains that are linked to one another by disulfide bonds. Lantus® differs from human insulin in that the physiochemical properties have been modified.
Voiceover: The amino acid asparagine at the position A21 is replaced by glycine and two arginines are added to the C terminus of the B chain.
Voiceover: The effect of these changes is to shift the isoelectric point, producing a solution that is completely soluble at pH 4.
Voiceover: When injected into the subcutaneous tissue, which has a physiologic pH of 7.4, the acidic solution is neutralized.
Voiceover: This leads to the formation of micro precipitates, from which small amounts of Lantus® are slowly released. Insulin crystals exist in hexamer form.
Voiceover: When micro precipitates develop, the hexamer is subdivided into three dimers, each of which divides into two monomers.
Voiceover: This slow dissolution of free hexamers results in a relatively constant concentration time profile over 24 hours with no pronounced peak. This profile is what allows Lantus® to be dosed once daily as a patient's basal insulin.
Lantus® (insulin glargine injection) 100 Units/mL
See how Lantus® provides effective, improved glycemic control in diabetes patients.†
†Lantus® Prescribing Information. August 2015.
Lantus® is a once-daily, long-acting insulin.**
**Lantus® Prescribing Information. August 2015.
Lantus® is a basal insulin with demonstrated long-term CV safety data††